

ELN and its mission

- International network for cooperative research to improve survival and the chances of cure of leukemia
- This is achieved by
 - spirit of cooperation
 - regular meetings
 - common projects
 - management recommendations on the highest international level with common definitions for each leukemia entity and interdisciplinary specialty
- More than 1000 clinicians and researchers
- 220 participating institutions
- 45 countries
- 10 000s of leukemia patients

ELN Structure

16 work package platforms (WP 1-15, 17)

Central service platforms


1. Network Management Center (NMC)
2. European Leukemia Information Services (ELIC)
3. Central Information and Communication Services (CICS)

Leukemia platforms

4. CML
5. AML
6. ALL
7. CLL
8. MDS
9. MPN

Interdisciplinary cooperation platforms

10. Diagnostics
11. Cytogenetis
12. Minimal residual Disease
13. Gene Profiling, NGS
14. Stem Cell Transplantation
15. Supportive Care, Anti- Infection
17. Biometry, Registry, Epidemiology



Selected Recommendations 2013-2024

Area	Title	Reference
ALL	Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel	Gökbuget et al. Blood 2024
	Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel	Gökbuget et al. Blood 2024
AML	Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel	Döhner et al. Blood 2022
AML/MRD	2021 Update on MRD in AML: a consensus document from the European LeukemiaNet MRD Working Party	Heuser et al. Blood 2021
APL	Management of APL: updated recommendations from an expert panel of the European LeukemiaNet.	Sanz et al. Blood 2019
CML	ELN Laboratory recommendations for diagnosis and management of CML	Cross et al. Leukemia 2023
	ELN 2020 Recommendations for treating CML	Hochhaus et al. Leukemia 2020
	ELN recommendations for the management and avoidance of adverse events of treatment in CML	Stegmann et al. Leukemia 2016
MPN	Inteferon alpha treatment for P. vera: ELN 2021 recommendations	Barbui et al. Lancet Hematology 2022
	Philadelphia chromosome-negative classical MPN: revised management recommendations from European LeukemiaNet	Barbui et al. Leukemia 2018
MDS	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from ELN	Malcovati et al. Blood 2013
Morphology	Harmonemia: a universal strategy for flow cytometry immunophenotyping – An ELN WP10 study	Lacombe et al. Leukemia 2016
SCT	Prophylaxis and treatment of graft versus-host disease	Ruutu et al. BMT 2013
Supportive care	ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients	Alanio et al. J Antimicrob Chemother. 2016
CLL	Immunoglobulin gene sequence analysis in CLL: updated ERIC recommendations	Rosenquist et al. Leukemia 2017
	A complementary role of multiparameter flow-cytometry and high-throughput sequencing for MRD detection in CLL: An ERIC study.	Rawstron et al. Leukemia 2016

● New centers in 2020

◀ ● New York
◀ ● Columbus
◀ ● Atlanta

◀ ● Las Palmas


● Seoul ▶
● Yekaterinburg ▶
● Novosibirsk ▶

● Bishkek ▶
● Tashkent ▶
● Yerevan ▶

● Doha ▶
● Riyadh ▶

220 centers in 45 countries

- 123 national leukemia study groups
- 114 interdisciplinary partner groups
- 1000 physicians and scientists
- Caring for ten thousands of patients





18. ELN Symposium with 21. KNL-Symposium
Mannheim, March 15, 2022